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Abstract
Background: Butyrate has been implicated in the mechanistic basis of the prevention of colorectal cancer by
dietary fibre. Numerous in vitro studies have shown that butyrate regulates cell cycle and cell death. More recently
we have shown that butyrate also regulates the integrity of the intermediate filament (IF) cytoskeleton in vitro.
These and other data suggest a link between the role of diet and the implication of a central role for the keratin 8
(K8) as guardian of the colorectal epithelium.
Methods: In this cross-sectional study possible links between butyrate levels, field effects and keratin expression in
cancer were addressed directly by analysing how levels of expression of the IF protein K8 in tumours, in adjacent
fields and at a distant landmark site may be affected by the level of butyrate in the colon microenvironment. An
immunohistochemical scoring protocol for K8 was developed and applied to samples, findings were further tested
by immunoblotting.
Results: Levels of K8 in colorectal tumours are lower in subjects with higher levels of faecal butyrate.
Immunoblotting supported this finding.Although there were no significant relationships with butyrate on the non-
tumour tissues, there was a consistent trend in all measures of extent or intensity of staining towards a reduction
in expression with elevated butyrate, consistent with the inverse association in tumours.
Conclusions: The data suggest that butyrate may associate with down-regulation of the expression of K8 in the
cancerized colon. If further validated these findings may suggest the chemopreventive value of butyrate is limited
to early stage carcinogenesis as low K8 expression is associated with a poor prognosis.
Background
The cytoskeleton of epithelial cells includes three princi-
pal types of filaments: microfilaments, microtubules, and
the intermediate filaments. Intermediate filaments are
formed from heteropolymers of type I and type II kera-
tins in epithelia, specifically keratin 8 (K8) and keratin
18 (K18) in the colon, with some expression of K7, K19,
and K20. Dimerisation of keratins is mediated through
pairing along their coiled-coil domains, and is regulated,
at least in part, through post-translational modification
of the globular domains outside these regions. Keratins
provide ability to the epithelium to withstand mechani-
cal strength as evident by the pathological phenotype
seen in patients with mutations in epidermal keratins
[1,2]. Analysis of the K8-null mouse revealed severe
disease of gastrointestinal tract characterized by colorec-
tal hyperplasia and inflammation [3].
Keratins not only provide mechanical strength but are
also involved in various regulatory functions of the cells.
Genetic knock-out experiments have revealed distinct
regulatory functions of K8 and K18 [4,5]. K8 plays an
important function in protecting the placental barrier
function [6]. K8 and K18 may regulate cell cycle and
cell growth: it is suggested that the absence of K8 or
K18 disturbs the cell cycle, drives cells into the G2-S
phase and leads to aberrant cytokinesis through phos-
phorylation of keratin and interaction with adaptor pro-
tein 14-3-3 [7]. It has been demonstrated that K8/K18
loss in mice leads to reduced hepatic size and protein
synthesis [8]. K8/K18 provide resistance to apoptosis on
stress and injury, and this effect may be mediated
through their effect on the death receptors (DR), Fas
and TNF-a. K8/K18-null mouse hepatocytes were less
resistant to Fas-mediated apoptosis [9]. Various
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abnormalities have been described in K8 deficient mice
including colonic hyperplasia [10,11], hypersensitivity of
the liver to stress [3,12], and alterations in intestinal
epithelial membrane proteins [13].
Human mutations in K8 or K18, the principal keratins
of gastrointestinal tract, have been shown to be asso-
ciated with cryptogenic cirrhosis and other liver disor-
ders [14]. Pancreatitis has also been shown an
association with K8 mutation [15]. A subset of patients
with ulcerative colitis has been shown to carry missense
mutations in the K8 or K18 genes. Reconstructions of
these mutations in vitro (K8: G62C, 163V, K464N; K18:
S230T) resulted in reduced filament assembly [16]. A
proteomic analysis of morphologically normal mucosa
from three group of colorectal patients: cancer, polyp
and normal showed the appearance of isoforms of K8 in
apparently normal mucosa in polyp and cancer patients,
compared with patients with no pathology [17]. Four K8
isoforms appeared in polyp mucosa relative to normal
mucosa and seven K8 isoforms appeared in cancer
mucosa relative to healthy mucosa. These findings indi-
cate alterations in K8, either at the level of expression
or modification in the morphologically normal mucosa
as the adenoma-carcinoma sequence progresses.
Another study showing differential K8 expression in col-
orectal carcinoma has shown reduced expression of K8
in colorectal cancer is significantly associated with
shorter patient’s survival, possibly on the basis of epithe-
lial-mesenchymal transition [18]. Taken together the
data from studies of both ulcerative colitis and adeno-
carcinoma pathologies suggests an important role for K8
and K18 in maintenance and stability of intestinal
epithelia. A characteristic of keratins is their relative sta-
bility of expression even after transformation to patholo-
gical state including transformation of normal cells into
malignant cells. This property has enabled keratins to be
applied as tumour markers [19].
Many epidemiological studies show an inverse rela-
tionship between dietary fibre intake and the incidence
of colorectal cancer, including the large EPIC study
[20]. One potential mechanism for the chemoprotective
effect of fibre is through the production of short-chain
fatty acids (SCFA) by fermentation in the colon lumen
and regulation of epithelial homeostasis. Among the
SCFAs butyrate is considered to be responsible for this
chemoprotection as it has major influence on cell cycle,
cell differentiation and cell death. Butyrate has been
shown to induce growth inhibition and terminal differ-
entiation in a variety of human colon cancer cell lines
[21-23]. Butyrate also triggers apoptosis in various cell
lines [24]. The ability of butyrate to alter various cell
functions is considered to be through ability to regulate
gene expression by inhibition of histone deacetylase
(HDAC) [25,26]. This results in hyperacetylation of
histone and enhancement of transcription factors and
activation or modulation of acetylated transcription fac-
tors such as Sp1 [27], nuclear structural proteins [28],
and p53 [29].
Given the importance of keratin expression and func-
tion to gastrointestinal function as evidenced by the
knockout mouse and heritable predisposition studies,
coupled with the ability of the chemopreventive butyrate
to regulate expression and function of proteins, we
sought to investigate what the effect of butyrate levels in
the colon microenvironment have upon expression and
localisation of K8 in the normal and neoplastic colon.
Methods
Recruitment and SCFA extraction
A total of 17 patients with colorectal cancer were
recruited for this study, 4 patients from surgical lists
and 13 from endoscopy lists [30]. Biopsies were taken
from three different sites in each patient as shown in
Table 1. All biopsies taken for immunohistochemistry
(IHC) were fixed in formalin and embedded in paraffin.
Stool samples were collected from each patient at least
two weeks after endoscopic procedures, for patients
recruited from Endoscopy list. Stool samples for patients
recruited from surgical lists were collected before sur-
gery. Stools were processed for SCFA extraction and
butyrate concentrations determined by gas chromatogra-
phy [31]. Ethics committee approval was obtained from
the North Sheffield Research Ethics Committee prior to
recruiting (Reference number: 06/Q2308/93). Subjects
included in this study were recruited between October
2007 and June 2008.
Immunohistochemistry
All biopsies were fixed for 24 hours in formalin before
paraffin embedding and cutting of serial 4-micron sec-
tions at 40-micron intervals. Antigen retrieval was per-
formed with EDTA (1 mM, pH8) in microwave at high
Table 1 Biopsying strategy for this study
Diagnosis Biopsy positions Other samples
Cancer 2x Mid-sigmoid for
proteomics
Stool, for short-chain fatty acid
determination, including butyrate
1x mid-sigmoid for
IHC
1x mid-sigmoid for
whole mount
Food frequency questionnaire
2x contralateral wall
(field) for proteomics
1x contralateral wall
(field) for IHC
2x lesion for
proteomics
1x lesion for IHC
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power for 8 mints. Avidin-biotin immunoperoxidase
technique was used and diaminobenzidine was used as
chromogen. Vectastain Universal RTU elite ABC kit, pk-
7200 was used for blocking agent, biotinylated secondary
and ABC reagent.
Sections were blocked with normal horse serum for 30
minutes at room temperature and then incubated with
primary antibody (K8 mouse monoclonal M20 [32] from
Abcam ab9023,, 1:200 dilution) for 60 minutes at room
temperature. Sections were incubated then with Biotiny-
lated secondary antibody (anti mouse IgG from RTU
Vectastain Universal elite ABC kit, Pk-7200) for 30 min-
utes followed by incubation with ABC reagent for 30
minutes. PBS (phosphate buffered saline) was used for
washes in between. Detection was performed using DAB
kit (Vector lab- sk-4100).
IHC Scoring for K8
Two slides containing three sections of each biopsy were
stained. A maximum of 6 well-oriented crypts per
biopsy, showing entire length of the crypt wall from the
base abutting the muscularis mucosa through to the
junction with the surface epithelium, were scored.
Images were captured at 20x magnification with a
Nikon D5-M camera at 2560 × 1920 resolution, stored
without compression and analysed using Nikon NIS-Ele-
ments D (v 2.30) software. Scoring was performed by
one observer blind to the status of the biopsy. A subset
of observations was confirmed by a second independent
observer.
Protein extraction and immunoblotting for K8
Eight pinch biopsies were selected according to buty-
rate levels (4 high and 4 low). A modification of the
intermediate filament extraction protocol described by
Herman et al [33] was performed, specifically using the
insoluble residue from biopsy lysis. The high-salt inso-
luble fraction (containing enriched intermediate fila-
ment proteins) was boiled in Laemmli buffer and
separated by SDS-Page prior to immunoblotting. Pri-
mary antibody (K8 mouse monoclonal, ab9023) was
used at 1:1000 concentration. The cross-reaction was
visualized using HRP-conjugated secondary antibodies
(Dako mouse for K8) and Western Lightning Chemilu-
minescence reagent plus (PerkinElmer, Boston, USA).
Imaging was performed with Chemigenius Bio-Imaging
system (Syngene).
Statistical tests
Graph Pad Prism 5.02 was used for statistical analysis.
Unpaired t-test was used to compare mean scores of K8
expression, including mucosal surface intensity, crypt
staining intensity and crypt staining extent between mid
sigmoid (MS) and contra lateral wall (CO). Unpaired
t-test was also used to find relationship of two groups of
butyrate with K8 expression in different parts including
cancer sites. Relationship of faecal butyrate levels and
K8 expression for all sites was also studied using Pear-
son correlation.
Results
Development of scoring criteria
Each biopsy from contralateral wall (CO) and mid sig-
moid (MS) area was scored in three categories: surface
staining intensity, crypt staining intensity relative to
surface staining, and extent of crypt staining. A maxi-
mum of six crypts from six available sections on two
slides were chosen for scoring from each biopsy.
Means were calculated for each category scored. Inten-
sity of surface staining was scored from 3 to 0, where
3 represented the best staining and 0 being minimal or
no staining. Intensity of crypt staining was compared
with intensity of surface staining and was scored 3 if
better than surface staining, 2 if similar to surface
staining and 1 if less than surface. Zero score was
awarded if minimal or no staining observed in crypt.
Score 3 was awarded if the whole extent of the crypt
was stained. Score 2 being 2/3 and 1 being 1/3 of the
crypt. If only few random cells were stained, that sec-
tion was considered negative for scoring purposes.
Immunohistochemical sections from cancer sites were
scored from 0 to 3 on the basis of proportion of cells
showing positive staining. Score 3 if more than 60% of
cells were positively stained for K8; 2 if around half of
the cells stained and 1 if less than 40% of the cells
were stained with K8.
Variation in K8 staining in normal tissue
K8 staining was observed as diffusely distributed in the
cytoplasm of the epithelial cells (Figure 1A). Expression
of K8 was noted to varying degrees along the crypt vil-
lus axis, and with varying intensities in the crypt and at
the mucosal surface. In total, immunohistochemical
data was available for 17 patients. Fifteen patients had
good sections for scoring purposes from both (MS and
CO) sites.
K8 mucosal surface staining intensity was not uni-
form in all sections. Examples of various staining
intensities at mucosal surface are shown in Figure 1A.
Figure 1, Panel Ai shows a weak staining intensity of
K8 at the surface mucosa (score1) compared to Panel
Aii (score2) and Panel Aiii which shows the highest
staining intensity (score3). Although there was varia-
tion of staining intensity among biopsies from different
patient at both sites, there was consistency among the
sections from the same biopsy. When staining intensi-
ties of crypts (at surface mucosa) were compared
between the landmark and the contralateral sites, 52%
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crypts shows strong staining intensity compared to
38% at the landmark site, with correspondingly fewer
sites showing weak staining (Figure 1B). These data
indicate a trend towards an increase in staining inten-
sity at surface mucosa during progression towards the
cancer from normal mucosa of the mid-sigmoid. This
is also evident from higher mean score (2.3) at CO
compared to MS (1.96) score (Figure 1C).
Examples of differing degrees of staining along the
crypt-villus axis are shown in Figure 2A. Figure 2A.i
shows an example of staining reaching the bottom third
of the crypt, whereas Figure 2A.iii shows an example of
K8 expression with poor crypt penetrance. Intermediate
examples, as shown in Figure 2A.ii, were also observed.
There was general within-subject consistency in terms
of staining pattern. The relative occurrence of each class
of staining extent is shown in Figure 2B. Most common
pattern seen both at MS (46.24%) and CO (53.57%) was
3, showing that staining reached up to lower third of
the crypt axis. In contrast to the findings for staining
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Figure 1 K8 surface expression at mid-sigmoid (MS) and contra-lateral wall (CO). (A) Examples of various surface staining intensities. A
weak staining at surface mucosa was scored 1 (Panel 1Ai) and the strong intensity was scored as 2 (Panel 1Aii). (B) Most common pattern both
at MS and CO was 3 suggesting that K8 expression is most strongly expressed at the mucosal surface (38.88% at MS and 52.94% at CO). (C)
Unpaired t-test shows a high mean value (2.3) at CO compared with MS (1.96) indicating a trend towards a higher surface expression of K8
around cancer compared to the distant mucosa.
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intensity, there was not a marked difference in the stain-
ing extent patterns between landmark and contralateral
sites. A mean score of less than 2 (1.75 at MS and 1.66
at CO) was observed for intensity of the crypt staining
(Table 2) implicating the stronger mucosal staining
compared to the intensity of crypt staining.
K8 patterns and scoring in cancer tissue
Biopsies from 14 patients’ cancer tissues were stained for
K8. There was a wide variation in staining patterns
probably because of regional heterogeneity of the tissue.
Only two samples showed a score of a less than 2 i.e. most
cancer tissues showed at least 50% expression of K8. None
of the sample was negative for K8 which is consistent with
previous results [34]. It was noted that highly undifferen-
tiated tumours have a very patchy distribution of K8
(Figure 3-Aii) whereas more differentiated tumours have a
pattern where cells along the mucosal surface were more
positive for K8 and deep cells were either negative or
showed less K8 expression (Figure 3A-iii).
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Figure 2 K8 expression along the crypt axis. Figure 2Ai shows K8 staining reaching to the bottom of the crypt, but in some crypts it reached
only the upper one third (Aii) and in others upper two third was stained with K8 (A-iii). The relative occurrence of each class of staining is show
in Figure 2B. Only few percent of crypts were without staining (5.37% in MS group and 8.62% in CO group) but majority of the crypts scored K8
staining reached to the bottom in both MS and CO (51.72% in CO and 46.24% in MS). There was no significant difference in the mean scores in
two groups (C).
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Figure 3 K8 expression in cancer tissue. Panels Ai-iii shows various examples of K8 expression scores in cancer tissue. Panel B: A significant
difference of K8 expression in cancer tissue was observed between high (mean = 5.46 mM) and low butyrate (mean = 2.36 mM) groups (p =
0.0056). Panel C shows immunoblots for K8 in cancer tissue: a total 8 samples were used, 4 with high faecal butyrate levels and 4 with low
faecal butyrate levels. Panel D: Densitometry result shows an inverse relationship between faecal butyrate levels and K8 expression in the cancer
tissue.
Table 2 Summary table of differences in staining between mucosal sites
Mid-sigmoid (mean) Contralateral Wall (mean) P value
Surface staining intensity 1.96 2.31 0.219
Crypt staining intensity 1.75 1.66 0.614
Extent of crypt staining 2.13 2.12 0.959
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Relationship between faecal butyrate levels and K8
expression in morphologically normal mucosa
Faecal butyrate scores were available for 9 patients.
Patients were split into haptiles by butyrate level (Low
butyrate group: 0-4 mM, mean 2.36; High butyrate
group >4 mM, mean 5.54). At the morphologically nor-
mal sites there was no statistically significant difference
in K8 expression between two butyrate groups in any of
the three categories of scoring (Table 3) both at either
mid sigmoid and field. However it was noted that all
scores showed a decrease from low to high butyrate,
indicating a consistent pattern or trend towards
decreased expression of K8 with elevated butyrate. Pear-
son correlation coefficient (Table 4) also did not reveal
any significant relationship between faecal butyrate
levels and K8 expression in any scored categories at all
three sites.
High butyrate levels are associated with low K8
expression in cancer tissue
Patient data was split into haptiles for butyrate level as
described above. Low and high butyrate groups were
compared for K8 expression (Figure 3B). A highly signif-
icant difference (p = 0.0056) was observed in two groups
with higher butyrate levels associated with a significant
decrease in K8 staining. Intermediate filament proteins
were extracted from duplicate samples and analysed for
level of expression by immunoblotting. All cross-react-
ing bands were quantified for the scoring purposes
(Figure 3C). Cross-reactions were quantitated from sub-
jects’ samples for higher and lower haptile by butyrate
concentration. These results also suggested a similar
inverse relationship between faecal butyrate levels and
K8 expression in cancer tissue (Figure 3C &3D)
although the considerable variation between samples
resulted in a non-significant finding.
Discussion
There is much emphasis on early detection of colorectal
cancer and for that reason knowledge of various protein
alterations which occur during carcinogenesis is impor-
tant. K8 is one of major keratins in the colorectal
mucosa. Through our scoring system we tried to
investigate any progressive change in K8 expression
from distant mucosa (MS in our study) to the cancer’s
field (CO) to the cancer. There was no significant differ-
ence in crypt staining intensity and crypt staining extent
but there was a clear trend towards higher K8 expres-
sion in the cancer’s field when compared to the distant
mucosa (MS) (Figure 1C). Polley et al. [17], using a pro-
teomic approach, also showed that there is an increase
in expression of some K8 isoforms in peri-adenomatous
fields. Polley et al. were unable to identify the isoform,
but there is consilience insofar as both independent stu-
dies find an increase in keratin 8 with cancer progres-
sion, including in the fields around cancer.
Our scoring system for K8 expression was used to
study possible relationships between the faecal butyrate
(as a proxy measure of lumenal butyrate), keratin
expression and colorectal cancer. We hypothesized that
K8 may be altered in colonic mucosa in response to
butyrate. Development of a scoring system in three cate-
gories including mucosal surface staining intensity, crypt
staining intensity, and extent of crypt staining allowed
testing of this hypothesis. Expression of K8 in tumours
was associated with butyrate level. These data were sup-
ported by western blot analysis using a K8-specific anti-
body to immunoprobe the insoluble protein (K8-rich)
fraction after biopsy lysis. We noted the appearance of
faster migrating forms on this blot. This could be attrib-
uted to an altered profile of phosphorylation, which has
been shown to link with cancer progression in the colon
[35], although phosphorylation at S73 and S431 was not
associated with an alteration in protein mobility in gels,
K8 is a highly modified molecule. It is our working
hypothesis that these bands represent proteolytically
cleaved forms associated with the cancer degradome
[36].
Taken alone the reduction in keratin 8 expression
associated with butyrate would be seen as a risk factor
for tumour progression [18], although data would need
to be interpreted against a wider panel protein altera-
tions to establish whether the global risk was actually
altered. A reduction in keratin expression is observed
during epithelial to mesenchymal transition, where
epithelial cytoskeletal proteins are replaced with proteins
Table 3 Summary table of differences in staining at mucosal sites by differing butyrate level
Tissue type Keratin expression score (mean) P value
Low butyrate (n = 5, mean = 2.4 mM) High butyrate group (n = 4, mean = 5.5 mM)
MS surface intensity 2.12 1.4 0.12
MS crypt intensity 1.84 1.66 0.6
MS crypt extent 2.24 1.76 0.44
CO surface intensity 2.44 2.15 0.58
CO crypt intensity 1.82 1.67 0.59
CO crypt extent 2.12 2.0 0.85
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more commonly associated with mesenchymal cells such
as vimentin. Although not particularly widely described
in colorectal oncology, progression through EMT is
associated with a poor prognosis. There are precedents
for nutrients associated with chemoprotective effects
actually to elevate risk in the cancerized colon, notably
folate [37].
One possible limitation of the study is the use of a
single sampling point for faecal butyrate. A recent
report highlighted the levels of intraindividual variation
in SCFA concentration and SCFA production are
labile, though it did suggest that concentrations were
more stable as a measure than total output [38]. We
reason that cells in the epithelium are exposed to a
concentration, not a production rate, and have used
this measure. We have found that other markers
strongly correlate with faecal butyrate [39] suggesting
relationships can be found, and that by implication the
relationship between faecal butyrate and keratin
expression is, at best, weak. A further hypothesis
which may account for these findings could be that
butyrate is a proxy measure of an unidentified bioac-
tive secondary metabolite which is modulating keratin
expression, or that direct interaction between butyrate-
producing endosymbionts and the mucosa mediates
this effect.
There was a consistent trend of increase in K8 expres-
sion in the morphologically normal tissues that did not
reach significance. This observation merits further study
to distinguish any possible causal role for K8 in cancer
progression and the potential of manipulation of the
colon luminal environment as a chemopreventive
strategy.
Conclusions
The pattern of K8 expression in normal and cancer
mucosa was reported by Fujiski [34]. Our data are con-
sistent with their findings and extend their findings by
providing a scoring system, by analysing the potential
relationship between K8 staining and butyrate, and by
cross-validating the data with a second independent
methodology. Our data suggest there may be an
increase in K8 expression from landmark to contralat-
eral fields (supporting the findings of Polley et al [17]).
We also suggest that there may be a very weak trend
for butyrate to reduce expression of K8 in morphologi-
cally normal tissue, but that this relationship is stronger
in tumour tissue.
Further studies could compare K8 expression in
apparently normal mucosa from normal screened popu-
lation and cancer patients, to establish whether there is
any progressive and identifiable change in K8 expression
during carcinogenesis.
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